- What is the primary focus of SBI JI Innovation Fund?
- SBI JI Innovation Fund, established in 2017, initially focused on biopharma. Following the successful conclusion of its initial bio fund's investment period, it is broadening its investment scope to include new high-tech sectors and territories.
- What types of companies does SBI JI Innovation Fund typically invest in?
- SBI JI Innovation Fund cherry-picks Israeli or Israel-related venture-backed biopharma and high-tech companies across different development stages, focusing on those with state-of-the-art scientific foundations, strong IP protection, world-class investors, experienced management, and rich therapeutic pipelines.
- What are the preferred sectors for investment by SBI JI Innovation Fund?
- SBI JI Innovation Fund prefers sectors such as biopharma, oncology, biotechnology, pharmaceuticals, fintech, cybersecurity, genetic disorders, immunology, immunotherapy, and high-tech.
- What investment stages does SBI JI Innovation Fund participate in?
- SBI JI Innovation Fund participates in a wide range of investment stages, from Seed to Series G, including Mature companies.
- What is the typical check size for investments made by SBI JI Innovation Fund?
- SBI JI Innovation Fund typically invests between $10 million and $78 million per deal.
- Where is SBI JI Innovation Fund headquartered?
- SBI JI Innovation Fund is headquartered in Tel Aviv-Yafo, Israel.
- Who are some of the key partners at SBI JI Innovation Fund?
- Key partners at SBI JI Innovation Fund include Masa Tanaka (President), Ryo Nakashima (Managing Director), David Heller (General Partner), Ran Gartenberg (General Partner & CFO), Hirohito Suzuki (Managing Director), and Ryosuke Hayashi (CEO & Managing Director).
- What is the origin of SBI JI Innovation Fund?
- SBI JI Innovation Fund was established in early 2017 as a collaborative venture between SBI Holdings, a prominent Japanese financial services group, and Vertex Israel, a leading Israeli venture capital firm.